Abstracts Archive - Page 568 of 2425 - ACR Meeting Abstracts

Abstract Number: 0236 • ACR Convergence 2021
Maternal Attachment, Anxiety and Depressive Symptoms in Pregnant Women with Rheumatic Diseases
Luis Gerardo Espinosa-Banuelos¹, Diana Carolina Rubio Torres², Maria Corral², Cassandra Skinner Taylor², Lorena Perez-Barbosa², Luz Fernanda Gutierrez Leal², Abraham Yair Lujano-Negrete³, Jesus Cardenas-de La Garza² and Dionicio Galarza-Delgado², ¹Faculty of Medicine and University Hospital Dr. Jose Eleuterio Gonzalez, UANL, Monterrey, Mexico, ²Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ³Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico
Background/Purpose: Untreated perinatal anxiety symptomatology can be related to symptoms of anxiety and depression during the postpartum. The psychological bond created by the mother between…
Abstract Number: 0239 • ACR Convergence 2021
Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Elaine Husni¹, Steven Peterson², Natalie Dennis³, Feifei Yang⁴, Iris Lin⁴, Yiting Wang⁵, Soumya Chakravarty⁶, Claire Fischer³, May Shawi⁷, Arthur Quenéchdu³ and Joseph Merola⁸, ¹Cleveland Clinic, Cleveland, OH, ²Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ³Amaris, Health Economics and Market Access, Paris, France, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Janssen R&D, LLC, Titusville, NJ, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). Fatigue has been shown to…
Abstract Number: 0238 • ACR Convergence 2021
The Impact of Preeclampsia on Pregnancies and Infants of Women with Rheumatic Disease
Megan Milne¹, Megan Clowse², Amanda Eudy¹, Congwen Zhao¹ and Ben Goldstein¹, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC
Background/Purpose: Rheumatic diseases, such as SLE, are associated with serious maternal, pregnancy, and infant complications. The role that preeclampsia plays in these outcomes in women…
Abstract Number: 0237 • ACR Convergence 2021
Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA
Jakub Zavada¹ and Lucie Nekvindova², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institut biostatistiky a analýz, spin-off společnost Masarykovy univerzity, Brno, Brno, Czech Republic
Background/Purpose: SF-36 and its components, as well as other PROs have been shown to predict various disease outcomes. We hypothesized that positive responses to questions…
Abstract Number: 0232 • ACR Convergence 2021
The Impact of Deucravacitinib on Health-Related Quality of Life Measured by the Short Form Health Survey 36-Item Questionnaire: Analysis of a Phase 2 Trial in Patients with Active PsA
Vibeke Strand¹, Philip Mease², Atul Deodhar³, June Ye⁴, Miroslawa Nowak⁴, Jiyoon Choi⁴ and Brandon Becker⁴, ¹Stanford University School of Medicine, Portola Valley, CA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ³Oregon Health & Science University, Portland, OR, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Patients (pts) with PsA experience pain, loss of physical function, joint damage, and significant impairments in social and emotional well-being. The Short Form Health…
Abstract Number: 0243 • ACR Convergence 2021
Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results from the PRCSG/PRINTO JIA Real-World Registry
Daniel Lovell¹, Nikolay Tzaribachev², Tracy Ting³, Ekaterina Alexeeva⁴, Teresa Giani⁵, Thomas Griffin⁶, John Bohnsack⁷, Andrew Zeft⁸, Richard Vehe⁹, Stacey Tarvin¹⁰, Gerd Horneff¹¹, Maria Trachana¹², Alyssa Dominique¹³, Lixian Dong¹³, Tzuyung Douglas Kou¹³, Robert Wong¹⁴, Alberto Martini¹⁵, Hermine Brunner³ and Nicolino Ruperto¹⁶, ¹Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ²PRI Research, Bad Bramstedt, Germany, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Scientific Center of Children Health of RAMS, Moscow, Russia, ⁵Università di Siena, Siena, Italy, ⁶Levine Children's Hospital, Charlotte, NC, ⁷University of Utah, Salt Lake City, UT, ⁸Cleveland Clinic, Cleveland, OH, ⁹University of Minnesota, Twin Cities, MN, ¹⁰Riley Hospital for Children at Indiana University, Indianapolis, IN, ¹¹Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ¹²Aristotle University of Thessaloniki, Thessaloniki, Greece, ¹³Bristol Myers Squibb, Princeton, NJ, ¹⁴Bristol Myers Squibb, Basking Ridge, NJ, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁶IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Long-term treatment with abatacept, a selective T-cell co-stimulation modulator, is effective and well tolerated in patients with JIA.1–4 The objective of this analysis was…
Abstract Number: 0242 • ACR Convergence 2021
FiRst Line Options for Systemic JIA Treatment (FROST): Results from a Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Consensus Treatment Plan Observational Study
Timothy Beukelman¹, George Tomlinson², Peter Nigrovic³, Anne Dennos⁴, Vincent Del Gaizo⁵, Mary Ellen Riordan⁶, Laura Schanberg⁷, Shalini Mohan⁸, Erin Pfeifer⁹ and Yukiko Kimura¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Toronto, Toronto, ON, Canada, ³Boston Children's Hospital, Brookline, MA, ⁴Duke University, Durham, NC, ⁵Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁶Hackensack University Medical Center, Westwood, NJ, ⁷Duke University Medical Center, Durham, NC, ⁸Genentech, Inc., South San Francisco, CA, ⁹Genentech, Inc., Englewood, CO, ¹⁰Hackensack University Medical Center, New York, NY
Background/Purpose: The optimal initial treatment for systemic juvenile idiopathic arthritis (sJIA) is unclear. To further study the initial treatment of sJIA, the Childhood Arthritis and…
Abstract Number: 0240 • ACR Convergence 2021
Economic Burden of Fatigue Among Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Joseph Merola¹, Feifei Yang², Natalie Dennis³, Steven Peterson⁴, Iris Lin², Yiting Wang⁵, Soumya Chakravarty⁶, Arthur Quenéchdu³, May Shawi⁷, Claire Fischer³ and Elaine Husni⁸, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ³Amaris, Health Economics and Market Access, Paris, France, ⁴Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ⁵Janssen R&D, LLC, Titusville, NJ, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Cleveland Clinic, Cleveland, OH
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). The objectives of this study…
Abstract Number: 0244 • ACR Convergence 2021
Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
Pamela Weiss¹, Timothy Brandon¹, Amita Aggarwal², Ruben Burgos-Vargas³, Robert Colbert⁴, Gerd Horneff⁵, Rik Joos⁶, Ronald Laxer⁷, Kirsten Minden⁸, Angelo Ravelli⁹, Nicolino Ruperto¹⁰, Judith Smith¹¹, Matthew Stoll¹², Shirley Tse⁷, Filip Van den Bosch¹³, Walter Maksymowych¹⁴, Robert Lambert¹⁵, David Biko¹⁶, Nancy Chauvin¹⁷, Michael Francavilla¹⁶, Jacob Jaremko¹⁵, Nele Herregods¹⁸, Ozgur Kasapcopur¹⁹, Mehmet YILDIZ²⁰ and Alison Hendry²¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ³Department of Rheumatology, General Hospital of Mexico, Ciudad de Mxico, Mexico, ⁴NIH/NIAMS, Bethesda, MD, ⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ⁶Ghent University, Ghent, Belgium, ⁷SickKids, Toronto, ON, Canada, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹Istituto Giannina Gaslini, Genoa, Italy, ¹⁰IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹¹University of Wisconsin, Madison, WI, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ¹⁴Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ¹⁵University of Alberta, Edmonton, AB, Canada, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷Penn State Health, Hershey, PA, ¹⁸Universitair Ziekenhuis Ghent, Ghent, Belgium, ¹⁹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ²⁰Istanbul University-Cerrahpasa, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ²¹NZ Familial GI Cancer Service, Auckland, New Zealand
Background/Purpose: As part of a larger study developing classification criteria for axial disease in children with spondyloarthritis (SpA), the objective of this project phase was…
Abstract Number: 0246 • ACR Convergence 2021
Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs
Betul Sozeri¹, Kenan Barut², Erdal Atalay³, Aysenur Pac Kisaarslan⁴, Semanur Ozdel⁵, Ozge Altug⁶, Ferhat Demir¹, Balahan Makay⁷, Nuray Aktay Ayaz⁸, Ersen Acar⁹, Fatih Haslak², Erdal Sag¹⁰, Mehmet YILDIZ², Ummusen Kaya Akca¹⁰, Amra Adrovic², Yelda Bilginer¹⁰, Hakan Poyrazoglu¹¹, Erbil Unsal⁷, Ozgur Kasapcopur¹² and Seza Ozen³, ¹University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ³Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey, ⁴Erciyes University Medical Faculty, Pediatric Rheumatology, Kayeri, Turkey, ⁵Ankara Dr.Sami Ulus Gynecology and Pediatrics Research and Training Hospital, Pediatric Rheumatology, Ankara, Turkey, ⁶Dr Behcet Uz Children's Hospital, Pediatric Rheumatology, Izmir, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Pediatric Rheumatology, Izmir, Turkey, ⁸Istanbul University, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ⁹Novartis, Istanbul, Turkey, ¹⁰Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ¹¹Erciyes University Faculty of Medicine, Pediatric Rheumatology, Kayseri, Turkey, ¹²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is the most acute and severe form of JIA. Despite the substantial evidence supporting the effectiveness of biologic drugs…
Abstract Number: 0245 • ACR Convergence 2021
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Hermine Brunner¹, Daniel Lovell², Michael Henrickson¹, Ruy Carrassco³, Kirsten Minden⁴, Lyudmila Grebenkina⁵, James Nocton⁶, Ingrid Louw⁷, Linda Wagner-Weiner⁸, Gabriel Vega Cornejo⁹, Sylvia Kamphuis¹⁰, Vyacheslav Chasnyk¹¹, Heather Walters¹², Simone Appenzeller¹³, Jordi Anton¹⁴, Alyssa Dominique¹⁵, Robert Wong¹⁶, Lixian Dong¹⁵, Tzuyung Douglas Kou¹⁵, Alberto Martini¹⁷ and Nicolino Ruperto¹⁸, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ³Presbyterian Health Services, Albuquerque, NM, ⁴Charite University Hospital Berlin, Berlin, Germany, ⁵Togliatti City Clinical Hospital №5, Togliatti, Russia, ⁶Medical College of Wisconsin, Milwaukee, WI, ⁷Panorama Medical Centre, Cape Town, South Africa, ⁸University of Chicago (Comer Children's), Chicago, IL, ⁹Crea de Guadalajara/Hospital México Americano, Guadalajara, Mexico, ¹⁰Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, Netherlands, ¹¹Saint-Petersburg State Pediatric Medical Academy, Saint Petersburg, Russia, ¹²Cohen Children's Hospital, New York, NY, ¹³Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ¹⁴Hospital Sant Joan de Deu, University of Barcelona, Barcelona, Spain, ¹⁵Bristol Myers Squibb, Princeton, NJ, ¹⁶Bristol Myers Squibb, Basking Ridge, NJ, ¹⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁸IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…
Abstract Number: 0241 • ACR Convergence 2021
Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA
yongdong Zhao¹, Erin Sullivan², Mary Beth Son³ and Timothy Beukelman⁴, ¹University of Washington, Redmond, WA, ²Seattle Children's Research Institute, Seattle, WA, ³Boston Children's Hospital, Brookline, MA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Paradoxical psoriasis has been increasingly reported in adults after exposure to tumor necrosis factor inhibitors (TNFi). Systematic studies in the pediatric population are lacking.…
Abstract Number: 0235 • ACR Convergence 2021
Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
Imke Redeker¹, Stefan Moustakis², Styliani Tsiami², Xenofon Baraliakos², Ioana Andreica², Bjoern Buehring², Juergen Braun² and Uta Kiltz², ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic…
Abstract Number: 0216 • ACR Convergence 2021
Distribution of Medial Femur and Tibia Cartilage Volume Change over 48 Months on MRI: Comparison Among Kellgren-Lawrence Grades
Rebecca Amesbury¹, Hedieh Ragati Haghi¹, Todd Laffaye¹, Rebekah Stein¹, Erin Ashbeck², C. Kent Kwoh³, Alexander Mathiessen¹ and Jeffrey Duryea¹, ¹Brigham and Women's Hospital, Boston, MA, ²University of Arizona Arthritis Center, Tucson, AZ, ³University of Arizona College of Medicine, Tuscon, AZ
Background/Purpose: Semi-automated Local Area Cartilage Segmentation (LACS) software uses two robust coordinate systems to measure cartilage change in focused regions in the femur and tibia.…
Abstract Number: 0187 • ACR Convergence 2021
Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
Vanessa Smith¹, Shervin Assassi², Yannick Allanore³, Lazaro Loaiza⁴, Inga Tschoepe⁵, Madhu Kanakapura⁴ and Elizabeth Volkmann⁶, ¹Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ²University of Texas McGovern Medical School at Houston, Houston, TX, ³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁵Elderbrook Solutions, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁶Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The efficacy and safety of nintedanib have been investigated in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial and in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].